These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15491745)

  • 1. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
    Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
    Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
    Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
    J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
    Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
    Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine in bladder cancer.
    El Karak F; Flechon A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3251-6. PubMed ID: 18035967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer.
    Brocks CP; Büttner H; Böhle A
    J Urol; 2005 Sep; 174(3):1115-8. PubMed ID: 16094076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
    Horinaga M; Fukuyama R; Iida M; Yanaihara H; Nakahira Y; Nonaka S; Deguchi N; Asakura H
    Urology; 2010 Nov; 76(5):1267.e1-6. PubMed ID: 21056277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
    Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
    Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
    Gårdmark T; Carringer M; Beckman E; Malmström PU;
    Urology; 2005 Sep; 66(3):527-30. PubMed ID: 16140071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
    Campodonico F; Canepa G; Capponi G; Bozzo L; Maffezzini M
    Anticancer Res; 2005; 25(3c):2381-4. PubMed ID: 16080464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).
    Gontero P; Casetta G; Maso G; Sogni F; Pretti G; Zitella A; Frea B; Tizzani A
    Eur Urol; 2004 Sep; 46(3):339-43. PubMed ID: 15306105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
    Campodonico F; Maffezzini M
    Urology; 2005 Nov; 66(5):1141-2; author reply 1142. PubMed ID: 16286156
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience.
    Mohanty NK; Nayak RL; Vasudeva P; Arora RP
    Urol Oncol; 2008; 26(6):616-9. PubMed ID: 18367121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
    Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
    J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical therapy for superficial cancer: need for more options.
    Crawford ED
    J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
    [No Abstract]   [Full Text] [Related]  

  • 16. [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
    Wang H; Liu Z; Wang ZP; Li FY; Zhao Y; Chen GP; Li DC
    Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):412-7. PubMed ID: 24119899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
    Gontero P; Marini L; Frea B
    BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
    Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
    J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
    Karavana SY; Şenyiğit ZA; Çalışkan Ç; Sevin G; Özdemir Dİ; Erzurumlu Y; Şen S; Baloğlu E
    Drug Des Devel Ther; 2018; 12():1959-1975. PubMed ID: 29997433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.